dacarbazine / Generic mfg. - LARVOL DELTA

Volcano-Like Lesions and Diffuse Gastrointestinal Metastases From Leiomyosarcoma Presenting With Melena (ACG 2026) - "He was treated with dacarbazine with a significantly good response, but was discontinued after ten months due to adverse effects. He then started on trabectedin; however, the follow-up imaging one year later demonstrated disease progression...The patient started on pazopanib and palliative radiation therapy...Prognosis remains poor once GI involvement occurs. Figure: Endoscopic images of GI Tract Involvement with Leiomyosarcoma: Section A: Colon leiomyosarcoma Section B: Duodenal leiomyosarcoma Section C: Stomach leiomyosarcoma Section D: Multiple lesions (LMS) involving the stomach Figure: Histopathological Images: Section A: Leiomyosarcoma involving colonic mucosa, consisting of perpendicularly oriented fascicles of brightly eosinophilic spindle cells Section B: CD117/kit is negative in the leiomyosarcoma, highlighting only scattered mast cells (immunoperoxidase, original magnification 20x) Section C: There is a strong diffuse expression of caldesmon (immunoperoxidase,..."

Gastric Cancer • Gastrointestinal Disorder • Gastrointestinal Stromal Tumor • Leiomyosarcoma • Sarcoma • Solid Tumor • ANO1 • CALD • KIT

A phase Ib/II study of the combination of lenvatinib (L) and eribulin (E) in advanced liposarcoma (LPS) and leiomyosarcoma (LMS) (LEADER): Efficacy updates. (ASCO 2022) - P1/2 | "Patients (pts) treated with E had an improved overall survival (OS) compared to dacarbazine but with an unsatisfactory 4% objective response rate (ORR). L + E had shown promising efficacy in advanced LMS and LPS. L at 14mg (vs 18mg) had a better AE profile without compromising activity. Future randomized study to confirm the efficacy of the combination is warranted."

Clinical • P1/2 data • Dermatology • Febrile Neutropenia • Hematological Disorders • Hypertension • Leiomyosarcoma • Liposarcoma • Neutropenia • Oncology • Renal Disease • Sarcoma • Soft Tissue Sarcoma • Solid Tumor

Advanced medullary thyroid cancer: is there a chance for chemotherapy? (ETA 2026) - "Lenvatinib allowed to achieve transient stabilization but, in October 2025, biochemical testing and imaging confirmed a further disease progression. Therefore, the patient started off-label chemotherapy consisting of 5-fluorouracil (5-FU) 400 mg/m² intravenous (IV) bolus, followed by 5-FU 2400 mg/m² as a 48-h infusion, combined with dacarbazine 800 mg/m² IV in 30 minutes, every 14 days (Nocera et al ., BJC 2000)...In conclusion, this case shows that, although conventional chemotherapy has been replaced in favour of TKI treatment, there are anecdotal cases in which it may be effective. Therefore, in case of failure of other approaches, chemotherapy should always be considered."

Metastases • Oncology • Solid Tumor • Thyroid Gland Carcinoma • Thyroid Gland Medullary Carcinoma • CA 19-9 • RET

Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin's Lymphoma. (PubMed, N Engl J Med) - P3 | "Patients who received A+AVD for the treatment of stage III or IV Hodgkin's lymphoma had a survival advantage over those who received ABVD. (Funded by Takeda Development Center Americas and Seagen; ECHELON-1 ClinicalTrials.gov number, NCT01712490; EudraCT number, 2011-005450-60.)."

Journal • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Neutropenia • Oncology • Pain • Transplantation

Nivolumab+AVD in Advanced-Stage Classic Hodgkin's Lymphoma. (PubMed, N Engl J Med) - P3 | "N+AVD resulted in longer progression-free survival than BV+AVD in adolescents and adults with stage III or IV advanced-stage classic Hodgkin's lymphoma and had a better side-effect profile. (Funded by the National Cancer Institute of the National Institutes of Health and others; S1826 ClinicalTrials.gov number, NCT03907488.)."

Clinical • Journal • Metastases • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology • Pediatrics

Camrelizumab combined with liposomal doxorubicin and dacarbazine as first-line therapy for advanced, recurrent, and metastatic undifferentiated pleomorphic sarcoma: A phase II study. (ASCO 2026) - P4 | "Camrelizumab combined with liposomal doxorubicin and dacarbazine demonstrated promising antitumor activity with durable responses and manageable safety as first-line therapy for advanced, recurrent and metastatic UPS. Exploratory analyses suggested that patients with higher PD-L1 expression may derive greater benefit from this regimen, warranting further investigation in larger, controlled studies. Clinical trial information: ChiCTR2100049974."

Clinical • IO biomarker • Metastases • P2 data • Hematological Disorders • Hepatology • Leukopenia • Neutropenia • Pneumonia • Sarcoma • Solid Tumor • Undifferentiated Pleomorphic Sarcoma • PD-L1

Variant Histology in Pediatric NLPBL: Adverse Biology Mitigated by R-CHOP, Including Feasible Early-Stage De-Escalation (SOHO 2026) - "Variant histology identifies a biologically and clinically higher-risk subgroup of pediatric NLPBL. However, this adverse impact appears to be mitigated by R-CHOP, with excellent outcomes—even in patients with variant histology. Our findings further suggest that risk-adapted de-escalation may be feasible in early-stage disease, including observation after complete resection and reduced-cycle R-CHOP for unresected stage 1–2 disease, without an apparent loss of efficacy."

Clinical • B Cell Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Nodular Lymphocyte Predominant Hodgkin Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Comprehensive Analysis of Treatment Related Morbidity and Progression -Free Survival in the GHSG Phase III HD21 Trial (ASH 2023) - P3 | "INTRODUCTION The GHSG-HD21 trial for newly diagnosed adult patients with advanced-stage classical Hodgkin lymphoma (AS-cHL) compares the BrECADD regimen (Brentuximab vedotin, etoposide, cyclophosphamide, doxorubicin, dacarbazine, dexamethasone) to eBEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procar­bazine, prednisone) in a PET adapted approach. Importantly, while the larger patient cohort of PET2-negative patients achieves a very high 3-yr PFS of 97% with a very short and safe 12-week treatment, this benefit was also observed for PET2-positive patients. In conclusion, the optimized risk-benefit ratio of the BrECADD regimen combined with the individualized PET2-guided treatment duration sets a new benchmark for the treatment of adult patients with newly diagnosed advanced stage cHL"

P3 data • Classical Hodgkin Lymphoma • Hematological Disorders • Hematological Malignancies • Hodgkin Lymphoma • Leukopenia • Lymphoma • Oncology • Thrombocytopenia

First-Line Treatment Patterns and Outcomes in Older Patients With Hodgkin Lymphoma in a Resource-Limited Setting: A Real-World Retrospective Single-Center Study (SOHO 2026) - "Five patients received the AEVD regimen (doxorubicin hydrochloride [Adriamycin], etoposide, vinblastine, and dacarbazine), of whom 3 were alive and disease-free at the time of analysis; outcome data for the remaining 2 patients were unavailable. This real-world experience suggests that bleomycin-sparing approaches, even without newer agents, are feasible in older patients with Hodgkin lymphoma and may offer a pragmatic treatment option in routine practice. In the absence of access to nivolumab or brentuximab vedotin, etoposide-based regimens could serve as a reasonable alternative. Larger prospective studies are warranted to better define optimal treatment strategies for this vulnerable population."

Real-world • Real-world evidence • Retrospective data • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology

First-line brentuximab vedotin plus chemotherapy to improve overall survival in patients with stage III/IV classical Hodgkin lymphoma: An updated analysis of ECHELON-1. (ASCO 2022) - P3 | "In ECHELON-1 (NCT01712490), 5-year follow-up analyses supported the long-term progression-free survival (PFS) benefit with first-line brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine (A+AVD) vs doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) in patients (pts) with stage III/IV cHL, independent of interim positron emission tomography status. A+AVD treatment resulted in a statistically significant 41% reduction in the risk of death vs ABVD, with a manageable safety profile consistent with prior reports. These outcomes confirm A+AVD as a preferred option for pts with previously untreated stage III/IV cHL."

Clinical • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology • Pain

Long-Term Follow-Up of the Response-Adapted Intergroup EORTC/LYSA/FIL H10 Trial for Localized Hodgkin Lymphoma. (PubMed, J Clin Oncol) - "Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.The primary analysis of the Early positron emission tomography (ePET) Response-Adapted Treatment in localized Hodgkin Lymphoma H10 Trial demonstrated that in ePET-negative patients, the risk of relapse increased when involved-node radiotherapy (INRT) was omitted and that in ePET-positive patients, switching from doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) to bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPPesc) significantly improved 5-year progression-free survival (PFS). In conclusion, the present long-term analysis confirms that in ePET-negative patients, the omission of INRT is associated with lower 10-year PFS. Instead, in ePET-positive patients, no significant difference between standard and experimental arms emerged..."

Journal • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology

Pembrolizumab and Involved Site Radiation Therapy Alone as an Alternative to Transplant in Patients with Localized Failure following Chemotherapy for Hodgkin Lymphoma: A Prospective Multicenter Phase II Study (ASTRO 2025) - "16 (89%) received doxorubicin/hydroxydaunorubicin, bleomycin, vinblastine, and dacarbazine (ABVD), 12 (67%) with <6 cycles...Subsequent treatment for the three patients currently in remission included pembro plus gemcitabine/vinorelbine/liposomal doxorubicin followed by ASCT (n=1), brentuximab vedotin (BV) plus nivolumab followed by ASCT (n=1) and 2 doses of BV followed by additional RT (n=1)... Pembro-RT yielded excellent CMR rates and minimal toxicity. These data suggest pembro-RT as a potential alternative to high dose chemo and SCT in localized, favorable relapsed/refractory HL. Enrollment to the study is complete and data will be updated prior to the meeting."

Clinical • P2 data • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology

2-YEAR FOLLOW-UP OF THE S1826 STUDY CONFIRMS IMPROVED PROGRESSION-FREE SURVIVAL WITH NIVOLUMAB-AVD COMPARED TO BRENTUXIMAB VEDOTIN-AVD IN ADVANCED STAGE CLASSIC HODGKIN LYMPHOMA (ISHL 2024) - "We hypothesized that introducing PD-1 blockade with nivolumab in combination with doxorubicin, vinblastine, and dacarbazine (N-AVD) would improve progression-free survival (PFS) over BV-AVD in AS cHL and evaluated this approach in the randomized, phase 3 S1826 study. N-AVD was better tolerated and improved PFS versus BV-AVD in adolescent and adult pts with AS cHL. Longer follow-up confirmed the PFS benefit with N-AVD at 2 y, including pre-specified subgroups. N-AVD is a new standard of care for treatment of AS cHL."

Metastases • Febrile Neutropenia • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Hematological Malignancies • Hodgkin Lymphoma • Immunology • Infectious Disease • Lymphoma • Musculoskeletal Pain • Neutropenia • Oncology • Pain • Pediatrics • Pneumonia

Nivolumab+AVD vs eBEACOPP in Advanced-Stage Classic Hodgkin Lymphoma: Single-Center, Nonrandomized, Prospective Clinical Trial (Real Clinical Practice) (SOHO 2026) - "N-AVD resulted in longer progression-free survival than eBEACOPP in adults with advanced-stage cHL and had a better side-effect profile. eBEACOPP: bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone in escalated doses, ECOG: Eastern Cooperative Oncology Group, HR: hazard ratio, N-AVD: nivolumab plus doxorubicin, vinblastine, and dacarbazine, PET-CT: positron emission tomography-computed tomography."

Clinical • Metastases • Classical Hodgkin Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology

Clinical Outcomes of PD-1/PD-L1 Inhibitors in Hematologic Malignancies: A Systematic Review Across Lymphoma, Leukemia, and Multiple Myeloma (SOHO 2026) - "Studies evaluating PD-1/PD-L1 inhibitors, including nivolumab, pembrolizumab, durvalumab, and atezolizumab, in lymphoma, leukemia, and MM were reviewed...In frontline advanced-stage cHL, nivolumab combined with AVD demonstrated improved PFS compared with brentuximab vedotin plus AVDin the SWOGS1826 trial... PD-1/PD-L1 inhibitors have significantly improved outcomes in cHL and continue to show potential in selected NHL subtypes. In contrast, their role in MM remains limited because of safety concerns and reduced efficacy, while data in leukemia are still evolving. Further studies are needed to better define the role of checkpoint inhibitors and combination immunotherapy strategies across different hematologic malignancies."

Clinical • Clinical data • Review • B Cell Lymphoma • Classical Hodgkin Lymphoma • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Leukemia • Lymphoma • Mediastinal B Cell Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Oncology • Primary Mediastinal Large B-Cell Lymphoma

Safety and Efficacy of ABVD Protocol in Pregnant Patients With Classic Hodgkin Lymphoma: A Single-Center Experience (SOHO 2026) - "All patients received doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) with or without involved-field radiotherapy. Therapeutic strategies were tailored, integrating symptomatic burden of disease, gestational age, and patient preferences to optimize the balance between maternal disease control and fetal outcomes. This cohort supports the safety profile of ABVD during pregnancy, including cases of advanced-stage cHL, while highlighting the critical necessity of multidisciplinary team involvement, shared decision-making, and comprehensive patient counseling."

Clinical • Classical Hodgkin Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology

Brentuximab Vedotin With Adriamycin, Vinblastine, and Dacarbazine for Patients Aged 18-59 Years With Untreated Advanced Stage Classical Hodgkin Lymphoma: The Largest Real-Life Series From Southern Italy Cancer Centers. (PubMed, Eur J Haematol) - P | "BV + AVD is increasingly used for frontline treatment of stage III/IV cHL. In Ya&A with high-risk cHL, our data suggest that a BV-driven strategy (without bleomycin and consolidation radiotherapy) is an effective up-front option in oncologic centers specialized in HL care, improving the rate of durable complete remission in routine clinical practice. Trial Registration: ClinicalTrials.gov identifier: NCT06857500."

Journal • Cardiovascular • Classical Hodgkin Lymphoma • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Neutropenia • Oncology • Pain

Evaluating the potential of candidate surrogate endpoints for overall survival in treatment-naive metastatic melanoma treated with anti-PD-1-based regimens with or without anti-CTLA-4 therapy. (PubMed, J Immunother Cancer) - "At the individual-level, ORR exhibited a strong correlation with OS, whereas PFS and TNTD showed a moderate level correlation with OS. At the trial level, the key requirement for validating surrogates, all candidate surrogates demonstrated moderate predictive abilities for OS in future trials. These findings should be interpreted within the context of anti-PD-1-based therapies, with or without anti-CTLA-4 combinations, consistent with the trial evidence base included in this study."

Clinical • Journal • Genetic Disorders • Melanoma • Oncology • Skin Cancer • Solid Tumor

Less Is More: Complete Metabolic Response With Low-Dose Nivolumab as Bleomycin Replacement for Stage 4 Classical Hodgkin Lymphoma (SOHO 2026) - "Brentuximab vedotin and standard-dose nivolumab (200 mg)—now preferred frontline substitutes—remain financially inaccessible in resource-limited settings. To our knowledge, this is the first reported case of low-dose nivolumab as a bleomycin substitute driven simultaneously by toxicity and affordability, a dual indication unrepresented in existing trials, warranting prospective validation. ABVD: doxorubicin, bleomycin, vinblastine, dacarbazine; AVD: doxorubicin, vinblastine, dacarbazine; cHL: classical Hodgkin lymphoma; CKD: chronic kidney disease; CR: complete response; ORR: objective response rate; PET-CT: positron emission tomography and computed tomography; PD-1: programmed cell death protein."

Metastases • Classical Hodgkin Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology

Brentuximab Vedotin and Nivolumab in Combination With Chemotherapy for Nonbulky, Early-Stage Classical Hodgkin Lymphoma. (PubMed, Blood) - P2 | "Most patients with early-stage classical Hodgkin lymphoma (cHL) are treated with doxorubicin, bleomycin, vinblastine, and dacarbazine with or without radiation therapy, although studies are now evaluating the incorporation of novel agents paired with abbreviated chemotherapy. Results from this study support the use of BV and nivolumab in combination with limited chemotherapy in patients with non-bulky, early-stage cHL. ClinicalTrials.gov: NCT03646123."

Journal • Classical Hodgkin Lymphoma • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Neutropenia • Oncology

EORTC-1537-COBRA: PHASE II STUDY OF VERY EARLY FDG-PET-RESPONSE ADAPTED TARGETED THERAPY FOR ADVANCED HODGKIN LYMPHOMA. PRIMARY ANALYSIS INCLUDING VALUE OF QUANTITATIVE PET ASSESSMENT AND TARC DYNAMICS (ISHL 2024) - "In cHL patients <60 years treated in the experimental arm of the ECHELON-1 study all patients received 6 x A-AVD (brentuximab vedotin, doxorubicin, vinblastine, dacarbazine) regardless of early PET results...The COBRA trial investigated early PET-response adapted treatment in BV-based first line therapy, by intensification to BrECADD (brentuximab vedotin, etoposide, cyclophosphamide, doxorubicin, dacarbazine, and dexamethasone) in patients PETpositive after 1 cycle of A-AVD. The primary endpoint of this phase II study was modified progression-free survival rate at 2 years from start of treatment (2 y mPFS)... Treatment adaptation based on a very early FDG-PET/CT leads to very high efficacy in advanced stage HL patients receiving BV-containing first-line treatment while sparing most patients intensive chemotherapy. Semiquantitative assessment of interim PET and/or TARC analysis enhances the positive predictive value of the early response assessment and can potentially..."

FDG PET • Metastases • P2 data • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology

PET-Guided Brecadd in Older Patients with Advanced-Stage Classic Hodgkin Lymphoma: Results of the Phase 2 Part of the GHSG HD21 Trial (ASH 2024) - P3 | "Background : PET-adapted therapy with four or six cycles of brentuximab vedotin, etoposide, cyclophosphamide, doxorubicin, dacarbazine and dexamethasone (4-6x BrECADD) is highly effective in patients up to 60 years with Advanced-stage classic Hodgkin lymphoma (AS-cHL; Borchmann P et al. Importantly, BrECADD resulted in an exceptionally high 2-year PFS rate, which is in the range observed for younger patients in HD21. We thus recommend PET-guided BrECADD as treatment strategy for newly diagnosed AS-cHL patients 61-75 years of age."

Clinical • Metastases • P2 data • Classical Hodgkin Lymphoma • Febrile Neutropenia • Hodgkin Lymphoma • Lymphoma

Positron Emission Tomography-Guided Brentuximab Vedotin, Etoposide, Cyclophosphamide, Doxorubicin, Dacarbazine, and Dexamethasone in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma: A Prospective, Multicenter, Single-Arm, Phase II Cohort of the German Hodgkin Study Group HD21 Trial. (PubMed, J Clin Oncol) - P3 | "PET-guided BrECADD in older patients is feasible and effective. With a PFS rate on par with that of younger patients, short duration, and limited anthracycline exposure, BrECADD is a valuable treatment option also for older patients with AS-cHL."

Journal • P2 data • Classical Hodgkin Lymphoma • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Hodgkin Lymphoma • Leukopenia • Lymphoma • Neutropenia • Oncology • Thrombocytopenia

Patient-Reported Chemotherapy-Induced Peripheral Neuropathy in Advanced-Stage Classic Hodgkin Lymphoma Treated With BrECADD and eBEACOPP: New Data From the HD21 Trial (SOHO 2026) - "Chemotherapy-induced peripheral neuropathy sensory symptoms occurred in both arms during treatment and decreased over FU and were generally less frequent in BrECADD-treated participants. Participants with these symptoms reported poorer overall health. Multiagent regimens for advanced-stage classic HL associated with fewer sensory symptoms may contribute to better overall health."

Clinical • Metastases • Classical Hodgkin Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology

Seven-year overall survival analysis from ECHELON-1 study of A+AVD versus ABVD in patients with previously untreated stage III/IV classical Hodgkin lymphoma. (ASCO 2024) - P3 | "Background: In ECHELON-1 (NCT01712490), 6-year follow-up (FU) analyses demonstrated significant improvements in overall survival (OS) and progression-free survival (PFS) with A+AVD (brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine) versus ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine), with a comparable safety profile. At 7-year median FU, pts with stage III/IV cHL who received A+AVD showed a sustained PFS and OS benefit vs ABVD, with PFS rates indicating potential curability. The safety profile in pts treated with A+AVD showed no new safety signals at 7 years."

Clinical • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology • Pain